NOVAVAX INC

Novavax’s VLP vaccine tech sparks investor buzz as stock hits key averages, yet profits lag—can the biotech company turn breakthrough into gains?

Novavax beats Q2 revenue, tightens costs, and deepens a Sanofi partnership to launch a COVID‑flu combo vaccine, boosting long‑term growth prospects.

Novavax’s VLP vaccine tech offers breakthrough promise, but its volatile stock and negative P/E reveal investor caution and the high risk of biotech innovation.

Novavax’s VLP vaccine tech shows promise, but its sharp stock swings and negative P/E highlight financial hurdles—will it become a biotech leader?

Novavax’s COVID‑19 vaccine strategy hinges on an FDA advisory vote, influencing its future VLP‑based products and investor sentiment.

Novavax’s Q1 2026 results reveal how its VLP tech and Matrix‑M adjuvant could reshape vaccine innovation, driving growth amid rising global health challenges.

Novavax faces a proxy battle as activist Shah Capital demands cost cuts, board shrinkage, and strategic review to unlock shareholder value.

Novavax’s turnaround: a profitable vaccine firm using VLP tech that’s climbing the Nasdaq, with strong earnings and growing investor interest.

Novavax insider purchase: director buys 8k shares and RSUs, showing strong confidence in VLP vaccine tech and future growth.

Novavax’s director boosts holdings, signaling confidence amid vaccine innovation and market volatility. Discover how this move reflects the company’s future prospects.